Molecular mechanisms linking early life seizures, autism and intellectual disabil

生命早期癫痫发作、自闭症和智力障碍之间的分子机制

• 批准号: 8217756
• 负责人: TIMOTHY A BENKE
• 金额: $ 33.24万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8217756
• 关键词: Address; Adult; Affect; Age; Animal Model; Autistic Disorder; Behavioral; Biochemical; Biochemical Pathway; Biological Assay; Chronic; Clinical; Cognitive; DLG4 gene; Data; Development; Electroencephalography; Environmental Risk Factor; Enzymes; Fragile X Mental Retardation Protein; Fragile X Syndrome; Functional disorder; Genetic; Hippocampus (Brain); Human; Intellectual functioning disability; Intervention; Life; Link; Long-Term Depression; MAPK3 gene; Measures; Mediating; Mediator of activation protein; Metabotropic Glutamate Receptors; Modality; Molecular; Muscarinic Acetylcholine Receptor; Newborn Infant; Other Genetics; Outcome; Pathway interactions; Patients; Pharmacological Treatment; Phenotype; Protein phosphatase; Proteins; Proto-Oncogene Proteins c-akt; Rattus; Reading; Ribosomal Protein S6 Kinase; Rodent Model; Saline; Seizures; Sensory Process; Signal Pathway; Signal Transduction; Socialization; Synapses; Synaptic plasticity; Testing; Translations; Tuberous Sclerosis; conditioned fear; cytochemistry; human FRAP1 protein; improved; in vivo; kainate; mouse model; novel; programs; protein expression; therapeutic target; translational study; treatment strategy

DESCRIPTION (provided by applicant): We seek to ultimately understand 3 basic questions: (1) Do early-life seizures (ELS) trigger intellectual disability (ID) with an autistic phenotype? (2) What signaling programs triggered by ELS potentially underlie this phenotype? (3) What are the rational, long-term pharmacological treatments to improve the abnormalities in synaptic plasticity and the in vivo phenotype? Our preliminary studies provide electrophysiological, pharmacological and biochemical evidence to suggest that ELS induces a chronic phenotype similar to other genetic forms of ID and autism such as Fragile X (FRAX) with FMRP dysfunction and Tuberous Sclerosis (TSC) with mTOR dysfunction. We propose three specific aims, utilizing electrophysiological, biochemical, immuno-cytochemistry and behavioral studies. Studies will use adult rats following a single kainate-induced ELS at post-natal day (P) 7. These studies will further investigate the mechanisms underlying altered mGluR-LTD measured electrophysiologically and test the hypothesis that ELS leads to a phenotype similar to other genetic forms of autism. Comparisons will be made to age-matched saline injected controls. Specific Aim 1: Determine the mechanisms underlying enhanced mGluR-dependent LTD observed following ELS. This will test the hypothesis that mGluR-dependent LTD is altered following ELS similar to that mediated by genetically disrupted FMRP expression and can be modified pharmacologically in a similar fashion. Specific Aim 2: Characterize the signaling pathways associated with S6 kinase (SK1) hyperactivation following ELS. This will test the hypothesis that signaling pathways are altered following ELS in a similar fashion to that mediated by disrupted FMRP expression and hyperactive mTOR, as in FRAX and TSC, respectively. Specific Aim 3: Further characterize the behavioral and electrographic in vivo phenotype following ELS. This will test the hypothesis that behavioral modalities beyond abnormal fear conditioning are induced by ELS that are consistent with an autism-like phenotype. By determining the pharmacological modulators of enhanced LTD following ELS, we will determine if this alteration in plasticity shares key features with that associated with FRAX and TSC. The pharmacological interventions advanced in FRAX and TSC are mirrored by our studies proposed here. Our studies will inform whether other forms of ID and autism potentially may share their pharmacological sensitivity and determine other potential therapeutic targets. These studies will advance the novel hypothesis that FMRP dysfunction can be seen in ID and/or autism outside of FRAX. This could impact treatment strategies for all causes of ID and/or autism. Our findings will support our hypothesis that seizures, as an external environmental factor, directly influence the development of ID and/or an autistic phenotype. These hypotheses cannot be tested in a straightforward fashion in patients. The use of our novel animal model of ELS triggering ID with an autistic phenotype allows these elusive clinical questions to be addressed more directly. PUBLIC HEALTH RELEVANCE: We seek to ultimately understand 3 basic questions: (1) Do early-life seizures (ELS) trigger intellectual disability (ID) with an autistic phenotype? (2) What signaling programs triggered by ELS potentially underlie this phenotype? (3) What are the rational, long-term pharmacological treatments to improve the abnormalities in synaptic plasticity and the in vivo phenotype? By determining the pharmacological modulators of enhanced LTD following ELS, we will determine if this alteration in plasticity shares key features with that associated with FRAX and TSC. The pharmacological interventions advanced in FRAX and TSC are mirrored by our studies proposed here. Our studies will inform whether other forms of ID and autism potentially may share their pharmacological sensitivity and determine other potential therapeutic targets. These studies will advance the novel hypothesis that FMRP dysfunction can be seen in ID and/or autism outside of FRAX. This could impact treatment strategies for all causes of ID and/or autism. Our findings will support our hypothesis that seizures, as an external environmental factor, directly influence the development of ID and/or an autistic phenotype. These hypotheses cannot be tested in a straightforward fashion in patients. The use of our novel animal model of ELS triggering ID with an autistic phenotype allows these elusive clinical questions to be addressed more directly.

描述（由申请人提供）：我们试图最终了解3个基本问题：（1）早期癫痫发作（ELS）是否会引发自闭症表型的智力残疾（ID）？(2)ELS触发的信号程序可能是这种表型的基础？(3)什么是合理的，长期的药物治疗，以改善突触可塑性和体内表型异常？ 我们的初步研究提供了电生理学、药理学和生物化学证据，表明ELS诱导了与其他遗传形式的ID和自闭症相似的慢性表型，如伴有FMRP功能障碍的脆性X染色体（FRAX）和伴有mTOR功能障碍的多发性硬化症（TSC）。 我们提出了三个具体的目标，利用电生理，生物化学，免疫细胞化学和行为研究。研究将使用出生后第7天（P）单次红藻氨酸诱导ELS后的成年大鼠。这些研究将进一步研究改变mGluR-LTD电生理测量的机制，并测试ELS导致与其他遗传形式的自闭症相似的表型的假设。将与年龄匹配的盐水注射对照进行比较。 具体目标1：确定ELS后观察到的增强mGluR依赖性LTD的潜在机制。这将检验mGluR依赖性LTD在ELS后改变的假设，其类似于由遗传破坏的FMRP表达介导的改变，并且可以以类似的方式进行修饰。 具体目标2：表征ELS后与S6激酶（SK 1）超活化相关的信号通路。这将检验以下假设：ELS后信号通路以与FMRP表达破坏和mTOR过度活化介导的方式相似的方式改变，分别如FRAX和TSC中。 具体目标3：进一步表征ELS后的行为和电图体内表型。这将测试这一假设，即超出异常恐惧条件反射的行为模式是由与自闭症样表型一致的ELS诱导的。 通过确定ELS后增强LTD的药理学调节剂，我们将确定这种可塑性改变是否与FRAX和TSC相关的关键特征相同。我们在此提出的研究反映了FRAX和TSC中先进的药理学干预。我们的研究将告知其他形式的ID和自闭症是否可能共享其药理学敏感性，并确定其他潜在的治疗靶点。这些研究将推进新的假设，即FMRP功能障碍可以在FRAX之外的ID和/或自闭症中看到。这可能会影响ID和/或自闭症的所有原因的治疗策略。我们的研究结果将支持我们的假设，癫痫发作，作为一个外部环境因素，直接影响ID和/或自闭症表型的发展。这些假设不能在患者中以简单的方式进行测试。使用我们的ELS触发ID与自闭症表型的新动物模型，可以更直接地解决这些难以捉摸的临床问题。 公共卫生相关性：我们试图最终理解3个基本问题：（1）早期癫痫发作（ELS）是否会引发自闭症表型的智力残疾（ID）？ (2)ELS触发的信号程序可能是这种表型的基础？ (3)什么是合理的，长期的药物治疗，以改善突触可塑性和体内表型异常？ 通过确定ELS后增强LTD的药理学调节剂，我们将确定这种可塑性改变是否与FRAX和TSC相关的关键特征相同。我们在此提出的研究反映了FRAX和TSC中先进的药理学干预。我们的研究将告知其他形式的ID和自闭症是否可能共享其药理学敏感性，并确定其他潜在的治疗靶点。这些研究将推进新的假设，即FMRP功能障碍可以在FRAX之外的ID和/或自闭症中看到。这可能会影响所有ID和/或自闭症病因的治疗策略。我们的研究结果将支持我们的假设，癫痫发作，作为一个外部环境因素，直接影响ID和/或自闭症表型的发展。这些假设不能在患者中以简单的方式进行测试。使用我们的ELS触发ID与自闭症表型的新动物模型，可以更直接地解决这些难以捉摸的临床问题。